Search

You searched for "partnerships"

323 results found

Planes, trams, and auditoriums: Beware predatory conferencing

4 December 2024 | | EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
Predatory open-access journals and predatory conferences are considered the two main areas of predatory infiltration in academic medicine that are of growing concern [1–7]. Unsolicited publishing requests from potentially predatory publishers occur frequently among faculty in ophthalmology [8]. Predatory conferencing...

Development of paediatric ophthalmology services in Malawi: the VISION 2020 LINK between Blantyre and Glasgow

5 August 2020 | | EYE - Paediatrics, EYE - Strabismus, EYE - Cataract, EYE - Refractive, EYE - General
A VISION 2020 LINK was established in 2005 between the Lions Sight First Eye Hospital (LSFEH) in Blantyre, Malawi (part of the Queen Elizabeth Central Hospital) with Glasgow’s Royal Hospital for Children to help to develop a paediatric ophthalmic service...

Addressing childhood blindness in sub-Saharan Africa

2 August 2024 | | EYE - Paediatrics, EYE - Strabismus
In this article, the authors explore paediatric ophthalmology subspecialist fellowship training in African nations south of the Sahara. Until recently, most African ophthalmologists who wished to pursue a subspecialty ophthalmology training fellowship had to go abroad. There is a huge...

Eye News to host educational day focused on AI and new technology

29 October 2019
We’re delighted to announce that we will be hosting a symposium again next year as part of Eyecare 2020.

Home testing can help glaucoma patients, new study shows

29 June 2021
Nearly 60,000 people in Scotland living with glaucoma could benefit from carrying out tests at home, a study funded by Sight Scotland and the Royal College of Surgeons of Edinburgh has shown.

Study shows laser treatment could significantly improve treatment for glaucoma in Africa

14 October 2021
Results of a trial published in Lancet Global Health on 14/10/21 could pave the way for significant improvements in treatment for glaucoma in Sub-Saharan Africa.

New Swansea eye hospital officially opened by Lord Mayor

6 April 2023 | spamedica, swansea, hospital
A new hospital specialising in NHS eye patient services has been officially opened by the Lord Mayor of Swansea, Councillor Mike Day.

New SpaMedica site opens in Bexhill-on-Sea

2 June 2023 | spamedica, infrastructure, Cataract surgery
SpaMedica, which specialises in NHS cataract surgery and YAG capsulotomy, will help to significantly reduce waiting times for East Sussex patients.

New eye hospital in North Tyneside marks major milestone for UK’s largest provider of NHS cataract surgery

20 September 2023 | spamedica, infrastructure, new hospitals, north tyneside
NHS cataract surgery patients will benefit from high-quality care and significantly reduced waiting times at SpaMedica’s 50th hospital.

CHEC ‘Re:Sets’ sights on patient outcomes and growth ambitions

21 September 2023 | CHEC, NHS, infrastructure, Industry
CHEC, one of the largest providers of community-based ophthalmology services in the UK, has launched an enhanced go-to-market strategy that will better align its service offerings and provision with the NHS’ evolving needs.

Requirements guidance issued as optometry contract for Wales comes into force

25 October 2023 | regulations, Wales, WGOS, EHEW, NHS Wales, optometry
Optometry Wales outlines new rules for practitioners practising in Wales.

Sight loss charities appoint engagement manager to oversee launch of new sight loss councils

9 February 2024 | Sight Scotland, Sight Scotland Veterans, charities, infrastructure, industry, Callum Lancashire
Sight Scotland, and Sight Scotland Veterans, in partnership with Visibility Scotland, have appointed Callum Lancashire as their new Engagement Manager to oversee the launch of Sight Loss Councils in Scotland.